[Atrial remodeling and anti-remodeling therapy in atrial fibrillation].
Neumann
T
T
Medizinische Klinik I, Kardiologie und Angiologie, Universitätsklinikum Giessen und Marburg.
Hölschermann
H
H
D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects; D017115:Catheter Ablation; D004562:Electrocardiography / Q000187:drug effects; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000009:adverse effects; D006325:Heart Atria / Q000187:drug effects / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D015525:Fatty Acids, Omega-3; D017923:Sodium-Hydrogen Exchangers; D000254:Sodium-Potassium-Exchanging ATPase; D000638:Amiodarone